<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387697</url>
  </required_header>
  <id_info>
    <org_study_id>TRICAVAL</org_study_id>
    <nct_id>NCT02387697</nct_id>
  </id_info>
  <brief_title>Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)</brief_title>
  <official_title>Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of implanting an Edwards
      Sapien XT Valve into the vena cava inferior (VCI; between right atrium and the hepatic vein)
      on clinical variables, exercise tolerance and well being in patients with severe tricuspid
      regurgitation and signs of right heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum relative VO2 uptake</measure>
    <time_frame>at 3 month</time_frame>
    <description>we consider the difference of means in maximum relative VO2 uptake at 3 months compared to control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ejection fraction (EF)</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right ventricular (RV) diameter</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right atrial (RA) diameter</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic vein diameter</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro Brain Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tricuspid regurgitation jet velocity time integral (as assessed by Doppler echocardiography)</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aerobic threshold (assessed by spiroergometry)</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilation efficiency (as assessed by the VE / VCO2 slope in spiroergometry)</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled rehospitalization</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea VAS</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minutes walk test</measure>
    <time_frame>day 30 and month 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Severe Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group (no surgery) with optimal medical treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Sapien XT Valve</intervention_name>
    <description>The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe symptomatic tricuspid regurgitation with a significant regurgitation jet into
             the caval and hepatic veins

          -  Optimal medical treatment

          -  High surgical risk with STS Score ≥ 10 or logistic EuroSCORE I ≥ 15 or any
             contraindication for conventional valve replacement/repair

          -  NYHA class of at least II

          -  Written informed consent

        Exclusion Criteria:

          -  VCI diameter &gt; 32 mm

          -  Severe left ventricular dysfunction with LVEF &lt; 30%

          -  Severe mitral insufficiency

          -  Estimated life expectancy &lt; 12months (360 days) due to carcinoma, chronic liver
             disease, chronic renal disease or chronic end stage pulmonary disease

          -  Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment

          -  Evidence of stroke / TIA during the last 180 days

          -  Leukopenia (WBC &lt; 3000 cell/mL), anemia (Hgb &lt; 9 g/dL), Thrombocytopenia (Plt &lt; 50,000
             cells/mL), or any known blood clotting disorder

          -  Evidence of an intracardiac mass, thrombus or vegetation

          -  Active upper GI bleeding within 1 month (30 days) prior to procedure

          -  Patients with an acute emergency

          -  Contraindication or hypersensitivity to all anticoagulation regimens, or inability to
             be anticoagulated for the study procedure

          -  Allergy against the use of implanted stent / prosthesis

          -  Patient undergoing regular dialysis or a serum creatinine above 3.0 mg/dl

          -  Patients unsuitable for implantation because of thrombosis of the lower venous system
             or vena cava filter

          -  Active bacterial endocarditis within 6 months (180 days) of procedure.

          -  Women of childbearing potential without highly effective contraception (PEARL-Index &lt;
             1%)

          -  Inability to comply with all of the study procedures and follow-up visits

          -  Subjects who are legally detained in an official institute (according to § 20 MPG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karl Stangl, Prof. Dr.</last_name>
    <phone>+49 30 450513075</phone>
    <email>karl.stangl@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Laule, PD Dr.</last_name>
    <phone>+49 30 450513103</phone>
    <email>michael.laule@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin, Medizinische Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Stangl, Prof. Dr. med</last_name>
      <phone>+49 30 450 513 142</phone>
      <email>karl.stangl@charite.de</email>
    </contact>
    <investigator>
      <last_name>Karl Stangl, Prof. Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Karl Stangl</investigator_full_name>
    <investigator_title>Prof. Dr. med Karl Stangl</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

